Compare APVO & DLPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APVO | DLPN |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 21.8M |
| IPO Year | N/A | N/A |
| Metric | APVO | DLPN |
|---|---|---|
| Price | $1.07 | $1.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 39.6K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $53,371,115.00 |
| Revenue This Year | N/A | $10.62 |
| Revenue Next Year | N/A | $13.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.86 |
| 52 Week Low | $1.04 | $0.75 |
| 52 Week High | $298.00 | $1.88 |
| Indicator | APVO | DLPN |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 42.77 |
| Support Level | $1.07 | $1.50 |
| Resistance Level | $1.41 | $1.70 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.46 | 28.57 |
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.